Immunic to participate in investor and scientific conferences in march

New york , march 2, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in march: march 9: biocapital europe. daniel vitt, ph.d.
IMUX Ratings Summary
IMUX Quant Ranking